Ìåíþ
Ãëàâíàÿ
Ñëó÷àéíàÿ ñòàòüÿ
Íàñòðîéêè
|
CD30, òàêæå èçâåñòíûé êàê TNFRSF8 — ïðîòåèí êëåòî÷íîé ìåìáðàíû èç ñåìåéñòâà ðåöåïòîðîâ äëÿ Ôàêòîðîâ íåêðîçà îïóõîëè.
CD30 ìîæåò áûòü ïðåäñòàâëåí â äâóõ ôîðìàõ — ìåìáðàííî-ñâÿçàííîé (ìîëåêóëà ôèêñèðîâàíà íà ïîâåðõíîñòè êëåòêè) è ðàñòâîðèìîé (soluble CD30, sCD30), ñåêðåòèðóåìîé àêòèâèðîâàííûì ëèìôîöèòîì.
Ìåìáðàííî-ñâÿçàííàÿ ôîðìà CD30 ïîÿâëÿåòñÿ íà ïîâåðõíîñòè àêòèâèðîâàííûõ Ò è  êëåòîê è å¸ âçàèìîäåéñòâèå ñ ñèãíàëüíûìè áåëêàìè TRAF2 è TRAF5[àíãë.] ïðèâîäèò ê àêòèâàöèè NF-kB.
Ñîäåðæàíèå
Âçàèìîäåéñòâèÿ
CD30 âçàèìîäåéñòâóåò ñ TRAF5[àíãë.][1], TRAF1[2], TRAF2[1][2] è TRAF3[2].
Ñì. òàêæå
Ïðèìå÷àíèÿ
- 1 2 Aizawa, S; Nakano H., Ishida T., Horie R., Nagai M., Ito K., Yagita H., Okumura K., Inoue J., Watanabe T. Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NFkappaB activation (àíãë.) // J. Biol. Chem. : journal. — 1997. — January (vol. 272, no. 4). — P. 2042—2045. — doi:10.1074/jbc.272.4.2042. — PMID 8999898.
- 1 2 3 Ansieau, S; Scheffrahn I., Mosialos G., Brand H., Duyster J., Kaye K., Harada J., Dougall B., Hbinger G., Kieff E., Herrmann F., Leutz A., Gruss H J. Tumor necrosis factor receptor-associated factor (TRAF)-1, TRAF-2, and TRAF-3 interact in vivo with the CD30 cytoplasmic domain; TRAF-2 mediates CD30-induced nuclear factor kappa B activation (àíãë.) // Proceedings of the National Academy of Sciences of the United States of America : journal. — 1996. — November (vol. 93, no. 24). — P. 14053—14058. — doi:10.1073/pnas.93.24.14053. — PMID 8943059. — PMC 19493.
Ëèòåðàòóðà- Schneider C., Hbinger G. Pleiotropic signal transduction mediated by human CD30: a member of the tumor necrosis factor receptor (TNFR) family (àíãë.) // Leuk. Lymphoma[àíãë.] : journal. — 2003. — Vol. 43, no. 7. — P. 1355—1366. — doi:10.1080/10428190290033288. — PMID 12389614.
- Horie R., Higashihara M., Watanabe T. Hodgkin's lymphoma and CD30 signal transduction (àíãë.) // Int. J. Hematol.[àíãë.] : journal. — 2003. — Vol. 77, no. 1. — P. 37—47. — doi:10.1007/BF02982601. — PMID 12568298.
- Tarkowski M. Expression and a role of CD30 in regulation of T-cell activity (àíãë.) // Curr. Opin. Hematol. : journal. — 2004. — Vol. 10, no. 4. — P. 267—271. — doi:10.1097/00062752-200307000-00003. — PMID 12799531.
- Granados S., Hwang S.T. Roles for CD30 in the biology and treatment of CD30 lymphoproliferative diseases (àíãë.) // J. Invest. Dermatol.[àíãë.] : journal. — 2004. — Vol. 122, no. 6. — P. 1345—1347. — doi:10.1111/j.0022-202X.2004.22616.x. — PMID 15175022.
- Drkop H., Latza U., Hummel M., et al. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease (àíãë.) // Cell : journal. — Cell Press, 1992. — Vol. 68, no. 3. — P. 421—427. — doi:10.1016/0092-8674(92)90180-K. — PMID 1310894.
- Fonatsch C., Latza U., Drkop H., et al. Assignment of the human CD30 (Ki-1) gene to 1p36 (àíãë.) // Genomics. — Academic Press, 1992. — Vol. 14, no. 3. — P. 825—826. — doi:10.1016/S0888-7543(05)80203-4. — PMID 1330892.
- Josimovic-Alasevic O., Drkop H., Schwarting R., et al. Ki-1 (CD30) antigen is released by Ki-1-positive tumor cells in vitro and in vivo. I. Partial characterization of soluble Ki-1 antigen and detection of the antigen in cell culture supernatants and in serum by an enzyme-linked immunosorbent assay (àíãë.) // Eur. J. Immunol.[àíãë.] : journal. — 1989. — Vol. 19, no. 1. — P. 157—162. — doi:10.1002/eji.1830190125. — PMID 2537734.
- Stein H., Gerdes J., Schwab U., et al. Identification of Hodgkin and Sternberg-reed cells as a unique cell type derived from a newly-detected small-cell population (àíãë.) // Int. J. Cancer[àíãë.] : journal. — 1983. — Vol. 30, no. 4. — P. 445—459. — doi:10.1002/ijc.2910300411. — PMID 6754630.
- Jung W., Krueger S., Renner C., et al. Opposite effects of the CD30 ligand are not due to CD30 mutations: results from cDNA cloning and sequence comparison of the CD30 antigen from different sources (àíãë.) // Mol. Immunol.[àíãë.] : journal. — 1995. — Vol. 31, no. 17. — P. 1329—1334. — doi:10.1016/0161-5890(94)90051-5. — PMID 7527901.
- Shiota M., Fujimoto J., Semba T., et al. Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3 (àíãë.) // Oncogene : journal. — 1994. — Vol. 9, no. 6. — P. 1567—1574. — PMID 8183550.
- Lee S.Y., Park C.G., Choi Y. T cell receptor-dependent cell death of T cell hybridomas mediated by the CD30 cytoplasmic domain in association with tumor necrosis factor receptor-associated factors (àíãë.) // Journal of Experimental Medicine[àíãë.] : journal. — Rockefeller University Press[àíãë.], 1996. — Vol. 183, no. 2. — P. 669—674. — doi:10.1084/jem.183.2.669. — PMID 8627180. — PMC 2192463.
- Gedrich R.W., Gilfillan M.C., Duckett C.S., et al. CD30 contains two binding sites with different specificities for members of the tumor necrosis factor receptor-associated factor family of signal transducing proteins (àíãë.) // J. Biol. Chem. : journal. — 1996. — Vol. 271, no. 22. — P. 12852—12858. — doi:10.1074/jbc.271.22.12852. — PMID 8662842.
- Horie R., Ito K., Tatewaki M., et al. A variant CD30 protein lacking extracellular and transmembrane domains is induced in HL-60 by tetradecanoylphorbol acetate and is expressed in alveolar macrophages (àíãë.) // Blood : journal. — American Society of Hematology[àíãë.], 1996. — Vol. 88, no. 7. — P. 2422—2432. — PMID 8839832.
- Aizawa S., Nakano H., Ishida T., et al. Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NFkappaB activation (àíãë.) // J. Biol. Chem. : journal. — 1997. — Vol. 272, no. 4. — P. 2042—2045. — doi:10.1074/jbc.272.4.2042. — PMID 8999898.
- Lee S.Y., Lee S.Y., Choi Y. TRAF-interacting Protein (TRIP): A Novel Component of the Tumor Necrosis Factor Receptor (TNFR)- and CD30-TRAF Signaling Complexes That Inhibits TRAF2-mediated NF-B Activation (àíãë.) // Journal of Experimental Medicine[àíãë.] : journal. — Rockefeller University Press[àíãë.], 1997. — Vol. 185, no. 7. — P. 1275—1285. — doi:10.1084/jem.185.7.1275. — PMID 9104814. — PMC 2196258.
- Boucher L.M., Marengre L.E., Lu Y., et al. Binding sites of cytoplasmic effectors TRAF1, 2, and 3 on CD30 and other members of the TNF receptor superfamily (àíãë.) // Biochem. Biophys. Res. Commun. : journal. — 1997. — Vol. 233, no. 3. — P. 592—600. — doi:10.1006/bbrc.1997.6509. — PMID 9168896.
- Duckett C.S., Thompson C.B. CD30-dependent degradation of TRAF2: implications for negative regulation of TRAF signaling and the control of cell survival (àíãë.) // Genes Dev. : journal. — 1997. — Vol. 11, no. 21. — P. 2810—2821. — doi:10.1101/gad.11.21.2810. — PMID 9353251. — PMC 316646.
- Mizushima S., Fujita M., Ishida T., et al. Cloning and characterization of a cDNA encoding the human homolog of tumor necrosis factor receptor-associated factor 5 (TRAF5) (àíãë.) // Gene[àíãë.] : journal. — Elsevier, 1998. — Vol. 207, no. 2. — P. 135—140. — doi:10.1016/S0378-1119(97)00616-1. — PMID 9511754.
- Kurts C., Carbone F.R., Krummel M.F., et al. Signalling through CD30 protects against autoimmune diabetes mediated by CD8 T cells (àíãë.) // Nature : journal. — 1999. — Vol. 398, no. 6725. — P. 341—344. — doi:10.1038/18692. — PMID 10192335.
|
|